Investment
Features
FeesSafety
Academy
More
Pluang+

GE Aerospace stock could rise 35% as analysts highlight strong backlog and new engine orders.

Analyst Insights
23 Sep 2026
Andrew Wynn
View Source
Bullish
GE Aerospace stock could rise 35% as analysts highlight strong backlog and new engine orders.

Jefferies analysts set a new price target of $435 for General Electric Aerospace, implying a 35% upside from its current price of around $321. GE Aerospace's strong position is supported by a $170 billion commercial services backlog and 80,000 aircraft in its installed base. The company recently secured 1,800 new engine orders, including a record order from IndiGo Airlines for over 1,000 LEAP-1A engines. Despite challenges like high oil prices and supply-chain issues, GE's growth strategy includes ramping up LEAP engine production and expanding defense programs, backed by strategic acquisitions to boost capacity and technology.

General Electric Aerospace is highlighted by Jefferies analysts' new price target of $435, suggesting a 35% upside from its current price near $321. For readers following Industrials-sector US stocks on Pluang, here is the market snapshot as of Sep 23, 2026 21:01 WIB: out of 93 priced stocks, 31 rose and 60 fell. Notable movers include Deere & Company (DE) at USD 719.63 with a 1-day change of +2.35% and Pluang order activity showing 81% Buy, JetBlue Airways Corporation (JBLU) at USD 4.43 down 2.64%, and Flux Power Holdings Inc (FLUX) at USD 0.52 down 2.51%.

More News

BNP Paribas cuts PepsiCo price target to $161, citing demand challenges but keeps Outperform rating.

BNP Paribas cuts PepsiCo price target to $161, citing demand challenges but keeps Outperform rating.

BNP Paribas lowered its price target for PepsiCo from $183 to $161 on September 23, 2026, due to ongoing demand challenges in North America. Despite the cut, the firm maintained an Outperform rating, indicating confidence in the stock's potential. Th...

Analyst Insights
Bearish
1 hour ago
Celldex's price target jumps to $88 after positive Phase III trial for chronic urticaria drug.

Celldex's price target jumps to $88 after positive Phase III trial for chronic urticaria drug.

Celldex Therapeutics saw its price target raised from $70 to $88 by Leerink Partners following successful Phase III trial results for its drug barzolvolimab treating chronic spontaneous urticaria (CSU). The trials met all primary endpoints, showing l...

Analyst Insights
Bullish
2 hours ago
Ero Copper stock holds steady with a raised price target amid plans to boost production by 2028.

Ero Copper stock holds steady with a raised price target amid plans to boost production by 2028.

Ero Copper, a major copper producer, shows stock volatility between $16.88 and $40.83 over the past year. Analyst firm CIBC maintained a "Neutral" rating but increased the price target to C$56.00, reflecting optimism about the company's long-term gro...

Analyst Insights
Bullish
2 hours ago
Cintas reports strong Q1 with EPS $1.39 and revenue up 10.9%, beating estimates.

Cintas reports strong Q1 with EPS $1.39 and revenue up 10.9%, beating estimates.

Cintas Corporation posted robust first-quarter results, surpassing analyst expectations with earnings per share of $1.39 and revenue of $3.01 billion, a 10.9% increase year-over-year. The company's organic revenue growth was 8.9%, reflecting solid bu...

Company Fundamentals
Bullish
2 hours ago
Oppenheimer cuts Nike price target to $52 amid sales drop and economic challenges, but sees 45% upside potential.

Oppenheimer cuts Nike price target to $52 amid sales drop and economic challenges, but sees 45% upside potential.

Oppenheimer lowered Nike's price target to $52 from a higher level, reflecting concerns over falling sales and macroeconomic challenges. Despite Nike's stock trading near its 52-week low around $35.35, the new target implies a potential 44.85% upside...

Analyst Insights
Bearish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App